User profiles for Denis Talbot
Denis TalbotUniversité Laval Verified email at fmed.ulaval.ca Cited by 2124 |
[HTML][HTML] Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment
…, S Tsim, N Kanellakis, H Ball, DC Talbot… - European …, 2016 - Eur Respiratory Soc
Malignant pleural mesothelioma is an aggressive malignancy of the pleural surface,
predominantly caused by prior asbestos exposure. There is a global epidemic of malignant pleural …
predominantly caused by prior asbestos exposure. There is a global epidemic of malignant pleural …
Duration of chemotherapy in advanced non–small-cell lung cancer: A randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin
IE Smith, MER O'Brien, DC Talbot… - Journal of clinical …, 2001 - ascopubs.org
PURPOSE: So far there are no published data on optimal duration of chemotherapy for
advanced non–small-cell lung cancer (NSCLC); six or more courses are usually recommended. …
advanced non–small-cell lung cancer (NSCLC); six or more courses are usually recommended. …
Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan–human epidermal growth factor receptor inhibitor, versus erlotinib in patients with …
…, I Bover, D Seog Heo, R Rosell, DC Talbot… - Journal of Clinical …, 2012 - ascopubs.org
Purpose This randomized, open-label trial compared dacomitinib (PF-00299804), an irreversible
inhibitor of human epidermal growth factor receptors (EGFR)/HER1, HER2, and HER4, …
inhibitor of human epidermal growth factor receptors (EGFR)/HER1, HER2, and HER4, …
Tirapazamine plus cisplatin versus cisplatin in advanced non–small-cell lung cancer: A report of the International CATAPULT I Study Group
…, M Boyer, LO Elisson, P Clark, D Talbot… - Journal of Clinical …, 2000 - ascopubs.org
PURPOSE: A phase III trial, Cisplatin and Tirapazamine in Subjects with Advanced Previously
Untreated Non–Small-Cell Lung Tumors (CATAPULT I), was designed to determine the …
Untreated Non–Small-Cell Lung Tumors (CATAPULT I), was designed to determine the …
[HTML][HTML] Protection against omicron (B. 1.1. 529) BA. 2 reinfection conferred by primary omicron BA. 1 or pre-omicron SARS-CoV-2 infection among health-care …
Background There is a paucity of data on vaccine-induced or infection-induced (hybrid or
natural) immunity against omicron (B.1.1.529) subvariant BA.2, particularly in comparing the …
natural) immunity against omicron (B.1.1.529) subvariant BA.2, particularly in comparing the …
A phase II study of etanercept (Enbrel), a tumor necrosis factor α inhibitor in patients with metastatic breast cancer
…, K Kaur, C Han, S Hoare, F Balkwill, DC Talbot… - Clinical Cancer …, 2004 - AACR
Purpose: Tumor necrosis factor (TNF) α is a key player in the tumor microenvironment and is
involved in the pathogenesis of breast cancer. Etanercept is a recombinant human soluble …
involved in the pathogenesis of breast cancer. Etanercept is a recombinant human soluble …
Two-dose SARS-CoV-2 vaccine effectiveness with mixed schedules and extended dosing intervals: test-negative design studies from British Columbia and Quebec …
…, S Setayeshgar, Y Febriani, M Ouakki, M Zou, D Talbot… - MedRxiv, 2021 - medrxiv.org
Background The Canadian COVID-19 immunization strategy deferred second doses and
allowed mixed schedules. We compared two-dose vaccine effectiveness (VE) by vaccine type (…
allowed mixed schedules. We compared two-dose vaccine effectiveness (VE) by vaccine type (…
Isolation of a small molecule inhibitor of DNA base excision repair
…, L Gardiner, S Houlbrook, DC Talbot… - Nucleic acids …, 2005 - academic.oup.com
The base excision repair (BER) pathway is essential for the removal of DNA bases damaged
by alkylation or oxidation. A key step in BER is the processing of an apurinic/apyrimidinic (…
by alkylation or oxidation. A key step in BER is the processing of an apurinic/apyrimidinic (…
Evidence for tumour necrosis factor/cachectin production in cancer
F Balkwill, F Burke, D Talbot, J Tavernier, R Osborne… - The Lancet, 1987 - Elsevier
Labile tumour-necrosis-factor-like (TNF) activity was detected by means of an enzyme-linked
immunosorbent assay in 50% of 226 freshly obtained serum samples from cancer patients …
immunosorbent assay in 50% of 226 freshly obtained serum samples from cancer patients …
[HTML][HTML] A randomized, crossover, head-to-head comparison of eicosapentaenoic acid and docosahexaenoic acid supplementation to reduce inflammation markers in …
…, A Charest, J Marin, MC Lépine, D Talbot… - The American journal of …, 2016 - Elsevier
Background: To date, most studies on the anti-inflammatory effects of eicosapentaenoic acid
(EPA) and docosahexaenoic acid (DHA) in humans have used a mixture of the 2 fatty acids …
(EPA) and docosahexaenoic acid (DHA) in humans have used a mixture of the 2 fatty acids …